Lexaria Bioscience Corp.
LEXX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001348362
No open-market purchases or sales by Lexaria Bioscience Corp. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $920.0K in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Lexaria Bioscience Corp. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 22 | 21 | −1 |
| Shares | 1.24M | 2.30M | +1.06M (+85.3%) |
| Value | $2.12M | $2.00M | −$120.2K (−5.7%) |
New holders (2)
Institutions that held Lexaria Bioscience Corp. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Sabby Management, LLC | 1,165,144 | $1.01M | 7.80% |
| UBS Group AG | 6,074 | $5.28K | 0.00% |
Sold out (3)
Institutions that held Lexaria Bioscience Corp. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Raymond James Financial Inc | 61,250 | $104.7K |
| HighTower Advisors, LLC | 21,000 | $35.9K |
| Sound Income Strategies, LLC | 22 | $38 |